The Strategy has been developed by a inter-ministerial working group composed of the Ministries of Health, Finance, Industry and Tourism and Science, Innovation and Universities, and the Main employers' associations in the pharmaceutical industry in Spain: Farmaindustria, BioSim, AESEG, AFAQUIM, ASEBIO, AELMHU and ANEFP.
There are several Proposals that directly affect biosimilar medicines: upward review of prices and differentiated reference sets under certain circumstances, a plan to encourage the use of biosimilars, clear criteria for pricing, and a registry and publication of actual use data.
Biosim sees the EIF as a “historic opportunity” in the face of the challenges of biosimilars
BioSim notes that the Pharmaceutical Industry Strategy will be a turning point in collaboration
BioSim welcomes the approval of the Pharmaceutical Industry Strategy
